Cardiovascular Therapeutics最新文献

{"title":"Endovenous Laser Ablation of Insufficient Superficial Veins in Patients After Deep Vein Thrombosis Recanalisation","authors":"Srdjan Babic,&nbsp;Jovan Petrovic,&nbsp;Masa Petrovic,&nbsp;Slobodan Pesic,&nbsp;Slobodan Tanaskovic,&nbsp;Ana Cvetkovic,&nbsp;Predrag Gajin,&nbsp;Nenad Ilijevski","doi":"10.1155/cdr/8458282","DOIUrl":"https://doi.org/10.1155/cdr/8458282","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>This study is aimed at investigating the safety of endovenous laser ablation treatment in the superficial venous system and perforator venous system in patients with previous deep vein thrombosis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>From February 2017 to January 2023, 28 patients (20 women) with an average age of 41.5 ± 8.6 years, insufficient great saphenous vein and previous deep vein thrombosis were treated. All patients were diagnosed based on previous ultrasound examinations. In this retrospective study, patients were indeed included if they met specific criteria. Preoperative evaluations and thrombophilia assessments were conducted.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Most patients had previous thrombosis in the popliteal vein (36.4%), while 31.8% had thrombosis in both the femoral and calf veins. Technical success was achieved in all patients, with concomitant procedures (closure of incompetent perforators and phlebectomies), and during follow-up (20 ± 16 months, range: 2–168 months), there were no signs of recanalisation of previously treated superficial veins. Patients were followed up at 1-month, 3-month, 6-month and 12-month intervals postprocedure. Recurrent deep vein thrombosis occurred in two (7%) patients after 26 and 31 months after treatment. Early complications included one (3.5%) case of endovenous heat-induced thrombosis Type II.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Endovenous laser ablation is safe and effective in patients with resolved deep vein thrombosis when combined with appropriate anticoagulant therapy.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9582,"journal":{"name":"Cardiovascular Therapeutics","volume":"2025 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/cdr/8458282","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145316952","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Single Fluoroscopy Versus Transesophageal Echocardiogram: A Comparative Evaluation for Left Atrial Appendage Occlusion With LACbes Device","authors":"Mingfei Li,&nbsp;Dawei Lin,&nbsp;Lei Zhang,&nbsp;Jianing Fan,&nbsp;Wenzhi Pan,&nbsp;Xiaochun Zhang,&nbsp;Daxin Zhou,&nbsp;Junbo Ge","doi":"10.1155/cdr/9933780","DOIUrl":"https://doi.org/10.1155/cdr/9933780","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>This study was aimed at evaluating the effectiveness of fluoroscopy as an intraprocedural guidance method during left atrial appendage occlusion (LAAO) using the LACbes device.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The study included a cohort of 477 patients with nonvalvular atrial fibrillation (AF) who underwent LAAO. The cohort was divided into two groups: a retrospective group of 240 patients who underwent standard procedures involving both transesophageal echocardiogram (TEE) and fluoroscopy and a prospective group of 237 patients who only underwent fluoroscopy. The retrospective cohort was analyzed for device positioning, anchoring, compression, and peridevice leak (PDL) using both TEE and fluoroscopy to provide detailed insights for potential application in the prospective cohort. Clinical outcomes were compared between the two groups.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>There were no significant differences in left atrial appendage (LAA) characteristics and other echocardiographic parameters between the two groups. Although the prospective group had a higher prevalence of implantation failure and more deployment attempts per procedure, these differences did not reach statistical significance. Notable differences were observed in fluoroscopy and operation times. Specifically, the prospective group had longer fluoroscopy times and more deployment attempts per procedure but shorter overall operation times compared to the retrospective group. Additionally, patients in the prospective group had shorter hospital stays and lower hospitalization costs. Periprocedural and 2-year follow-up complications were comparable between both cohorts, with no statistically significant differences observed in pericardial effusion, peripheral vascular complications, survival, cardiac death, PDL, or device thrombus.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The use of fluoroscopy as the sole guidance modality for LAAO with the LACbes device demonstrated promising results in terms of efficacy and safety. It emerges as a viable and cost-effective alternative, offering a more efficient approach for LAAO.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9582,"journal":{"name":"Cardiovascular Therapeutics","volume":"2025 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/cdr/9933780","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145316766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metformin Attenuates Myocardial Ischemia–Reperfusion Injury in Rats by Modulating JNK Pathway and Inhibiting PANoptosis Mechanisms","authors":"Biao Hou,&nbsp;Xuejian Hou,&nbsp;Liyue Zhang,&nbsp;Tingting Liu,&nbsp;Yang Li,&nbsp;Ran Dong","doi":"10.1155/cdr/4642838","DOIUrl":"https://doi.org/10.1155/cdr/4642838","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Purpose</h3>\u0000 \u0000 <p>Myocardial ischemia–reperfusion injury (MIRI) is a condition in which the heart is aggravated when blood flow is restored after tissue damage caused by ischemia. Metformin (Met), a widely prescribed antidiabetic medication, has demonstrated promising cardioprotective properties, particularly through its anti-inflammatory, antiapoptotic, and metabolic regulatory mechanisms. This study investigates the cardioprotective effects of Met in a rat model of MIRI, focusing on its modulation of the c-Jun N-terminal kinase (JNK) pathway and inhibition of PANoptosis mechanisms.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The proportion of myocardial infarction was determined by triphenyl tetrazole chloride (TTC) staining. Wheat germ agglutinin (WGA) staining is used to determine whether myocardial cells are hypertrophic and other pathological conditions. Serum markers of myocardial injury along with inflammatory cytokines were measured by enzyme-linked immunosorbent assay (ELISA). Immunofluorescence and Western blotting were employed to evaluate myocardial cell PANoptosis and the involvement of the JNK pathway.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>After MIRI, TTC staining revealed apparent myocardial infarction, and WGA staining showed significant myocardial cell hypertrophy. There was also a marked increase in myocardial injury markers, inflammatory factors, and reactive oxygen species (ROS). Met significantly reduced the myocardial injury area and notably lowered serum levels of c-TnI, CK-MB, LDH, IL-6, TNF-<i>α</i>, and ROS. Immunofluorescence and Western blot analyses demonstrated that Met attenuates myocardial cell PANoptosis by inhibiting JNK phosphorylation and reducing ROS generation. The cardioprotective effect of Met was reversed by the addition of anisomycin (ANI). The protective effect of JNK-specific inhibitors administered as monotherapy was found to be comparable to that of Met. The aforementioned results suggest that the regulation of the JNK pathway is a critical factor contributing to its protective effect.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The cardioprotective effect of Met in the rat model of MIRI is mediated through the regulation of the JNK pathway and PANoptosis. These findings suggest that Met may provide a potential therapeutic approach for treating MIRI.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9582,"journal":{"name":"Cardiovascular Therapeutics","volume":"2025 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/cdr/4642838","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145271800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimization of Clinical Trial Design and Decision-Making for Heart Failure with Preserved Ejection Fraction (HFpEF): A Meta-Analysis Based on a Placebo Response Model","authors":"Xiaoya Chen,&nbsp;Juan Yang,&nbsp;Ling Xu,&nbsp;Fang Yin,&nbsp;Jihan Huang,&nbsp;Yinghua Lv,&nbsp;Qingshan Zheng,&nbsp;Lujin Li","doi":"10.1155/cdr/7087720","DOIUrl":"https://doi.org/10.1155/cdr/7087720","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>The aim of this study was to establish a placebo response model for efficacy indicators in heart failure with preserved ejection fraction (HFpEF) clinical trials, facilitating sample size estimation and trial optimization.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>PubMed, EMBASE, and Cochrane Library databases were searched systematically for placebo-controlled trials of HFpEF up to May 26, 2024. Using model-based meta-analysis (MBMA), we analyzed cardiovascular death or heart failure hospitalization, cardiovascular death, heart failure hospitalization, all causes of death, and changes from baseline in the 6-min walk distance (6MWD) of the placebo group. The final model simulated the placebo effect distribution for these indicators under varying scenarios.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 29 studies and 14,302 participants were analyzed. A log-normal risk function was developed to describe four event rate indicators, and typical event rates for the placebo group over 6 years were simulated. After 1 year, rates for cardiovascular death or heart failure hospitalization (composite event), heart failure hospitalization, all causes of death, and cardiovascular death were 11.1%, 10.5%, 2.91%, and 2.33%, respectively. We used a linear model to describe the time–effect relationship of the change value of change from baseline in 6MWD, revealing typical changes at 1, 3, and 6 months as 1.47, 4.76, and 9.57 m, respectively. These values indicated that using the composite event as criteria could reduce the sample size by 500–12,000 cases, while 548 cases were sufficient for changes in 6MWD. The placebo effect model was also used as an external control in evaluating Sacubitril/Valsartan and exercise training efficacy.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This placebo response model provides essential support for sample size estimation, trial optimization, and drug efficacy evaluation in future HFpEF clinical trials.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9582,"journal":{"name":"Cardiovascular Therapeutics","volume":"2025 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/cdr/7087720","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145271764","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HTR2B-Mediated Endothelial Protection: Modulating Ferroptosis via the PI3K/AKT Signaling Pathway in Atherosclerosis","authors":"Delin Li,&nbsp;Hui Li,&nbsp;Quanwei Zhao,&nbsp;Caiwei Gong,&nbsp;Long Chen,&nbsp;Chengzhu Xiong,&nbsp;Shaoliang Shen,&nbsp;Fujun Liao,&nbsp;Wupeng Liu,&nbsp;Danan Liu","doi":"10.1155/cdr/7934590","DOIUrl":"https://doi.org/10.1155/cdr/7934590","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>The current study is aimed at elucidating the mechanisms underlying the involvement of ferroptosis in atherosclerosis (AS) and exploring potential therapeutic targets.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Endothelial function and lipid peroxidation were assessed in vitro using HCAECs treated with OX-LDL. SLC7A11, GPX4, TfR1, and FTH1 were analyzed by western blot, respectively. Representative markers of ferroptosis including LDH, MDA, 4-HNE, GSH, and iron content were detected. HTR2B miRNA (OE-HTR2B) and controls (OE-NC, empty vector) were transfected. AS was induced in ApoE^-/- mice through a high-fat diet. The effect of ferroptosis inhibition on atherosclerotic lesion development was evaluated by different inhibitor treatments.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>RNA-Seq analysis revealed dysregulated <i>HTR2B</i> expression in HCAECs exposed to OX-LDL, indicating its involvement in AS pathogenesis. OX-LDL exposure reduced cell viability and induced ferroptosis, characterized by decreased SLC7A11 and GPX4 expression and increased lipid peroxidation. Overexpression of <i>HTR2B</i> rescued cell viability, reduced Fe²⁺ accumulation, and upregulated SLC7A11 and GPX4, suggesting a protective role against ferroptosis. Further, <i>HTR2B</i> regulated ferroptosis via the PI3K/AKT pathway, as evidenced by changes in pathway protein phosphorylation. By activating HTR2B with an agonist BW-723C86, we verified that <i>HTR2B</i> can inhibit ferroptosis through the PI3K/AKT pathway in an atherosclerotic mouse model.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>HTR2B suppressed ferroptosis by promoting the PI3K/AKT axis, enhanced cellular viability, and exhibited a protective role in AS.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9582,"journal":{"name":"Cardiovascular Therapeutics","volume":"2025 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/cdr/7934590","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145223804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"“RotaTripsy” as State-of-the-Art Strategy for Coronary Artery Calcification: A Scoping Review","authors":"Tianxu Hao,&nbsp;Zhenchun Song,&nbsp;Jiechun Li,&nbsp;Rui Suo,&nbsp;Yan Li,&nbsp;Yibei Lu,&nbsp;Ximing Li,&nbsp;Dongxia Jin","doi":"10.1155/cdr/3713315","DOIUrl":"https://doi.org/10.1155/cdr/3713315","url":null,"abstract":"<p><b>Background:</b> Recently, the combination of rotational atherectomy (RA) with intravascular lithotripsy (IVL), known as “RotaTripsy,” has been employed in the treatment of coronary lesions with severe calcification. In this article, we provide an overview of the current evidence regarding this technique, emphasizing the importance of appropriate patient and lesion selection to achieve optimal clinical outcomes, including the primary goal of improvement of stenting and enhancement of short and long-term prognosis.</p><p><b>Methods:</b> We performed a systematic literature search using PubMed, Embase, Web of Science, and Cochrane library up to July 2024 for studies that combined RA and IVL for coronary artery calcification lesions that were included. The retrieved articles and references of the primary articles were used to collect the basic information. SPSS 20.0 and Excel statistic software were used to conduct this scoping review.</p><p><b>Results:</b> A total of 25 studies consisting of 259 patients were identified. Of all the patients, 208 (80.3%) were male. Patients had an average age of 68.31 years, and 119 (45.95) patients had acute coronary syndrome. In addition, 218 (84.17%) had hypertension, 128 (49.42%) had diabetes mellitus, and 48 (18.53%) had chronic kidney disease. In the ultimate analysis, 252 patients (97.3%) successfully underwent the “RotaTripsy” procedure, with a minimal mortality rate of only 7 individuals (2.7%) during the follow-up period.</p><p><b>Conclusions:</b> “RotaTripsy,” as an efficacious therapeutic modality, shows its unique potential for severe calcified coronary artery lesions resistant to dilation. Our research findings substantiate its feasibility, safety, and effectiveness in clinic.</p>","PeriodicalId":9582,"journal":{"name":"Cardiovascular Therapeutics","volume":"2025 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/cdr/3713315","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145110918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fibroblast Activation Protein-Targeted CAR-T Cells Induce Apoptosis in Murine Cardiac Myofibroblasts","authors":"Hao Li,&nbsp;Qi Zheng,&nbsp;Yongliang Jiang,&nbsp;Lin Yang,&nbsp;Shuangxiu Li,&nbsp;Ping Yang,&nbsp;Gaosheng Yin,&nbsp;Lin Sun","doi":"10.1155/cdr/7230505","DOIUrl":"https://doi.org/10.1155/cdr/7230505","url":null,"abstract":"<p>Myocardial fibrosis is a common pathological feature in many cardiovascular diseases, yet effective targeted therapies remain elusive. Given the emerging potential of chimeric antigen receptor T (CAR-T) cell therapy in nononcological diseases and fibroblast activation protein (FAP) as a promising target, we engineered a second-generation FAP-targeted CAR construct incorporating the 4-1BB costimulatory domain to enhance therapeutic safety. Using two delivery approaches—lentiviral vectors and lipid nanoparticles (LNPs)—we generated FAP-CAR–engineered Jurkat cells as a preliminary screening model and evaluated their CAR expression, target recognition, and in vitro cytotoxic activity. These engineered cells selectively recognized and induced apoptosis in FAP-expressing cardiac myofibroblasts without triggering excessive IL-6 secretion, supporting their potential for fibrosis-selective cytotoxicity. Our findings provide key preliminary in vitro evidence supporting the design and target-specific functionality of FAP-targeted CAR constructs incorporating the 4-1BB domain, warranting further investigation in primary T cell models for cardiac fibrosis therapy.</p>","PeriodicalId":9582,"journal":{"name":"Cardiovascular Therapeutics","volume":"2025 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/cdr/7230505","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145038294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inhibition of lnc-COL6A1-6-Alleviated Osteogenic Differentiation of Valvular Interstitial Cells During Aortic Valve Calcification","authors":"Ying Gu,&nbsp;Fan Yang,&nbsp;Quangong Zhao,&nbsp;Jingwen Zhou,&nbsp;Xiangyang Xu,&nbsp;Yang Yuan,&nbsp;Xian Guo,&nbsp;Zhigang Song,&nbsp;Zhiyun Xu,&nbsp;Guokun Wang","doi":"10.1155/cdr/2277191","DOIUrl":"https://doi.org/10.1155/cdr/2277191","url":null,"abstract":"<p><b>Background:</b> Calcific aortic valve disease (CAVD) is a prevalent valvular heart disease characterized by the fibrocalcific remodeling of the aortic valves, leading to significant health issues among the elderly population worldwide. The aberrant expression of long noncoding RNAs (lncRNAs) is closely associated with the pathogenesis of various diseases.</p><p><b>Methods and Results:</b> A total of 241 differentially expressed lncRNAs were identified in calcified aortic valve tissues (fold change of ≥ 2 and <i>p</i> value &lt; 0.05), including 65 upregulated and 176 downregulated lncRNAs. The expression of the Top 5 upregulated lncRNAs was monitored during the calcification of valvular interstitial cell (VIC). Notably, the expression of lnc-PRDM8-3 and lnc-COL6A1-6 in VICs increased significantly after calcification induction and was sustained at high levels. Inhibition of lnc-COL6A1-6, but not lnc-PRDM8-3, obviously alleviated the calcification of VICs, as evidenced by a marked reduction in calcium deposition, decreased alkaline phosphatase activity, and downregulated expression of Runx2 and OPN. Bioinformatic analysis predicted that lnc-COL6A1-6 might serve as a competing endogenous RNA for 11 miRNAs, potentially regulating the expression of 784 target genes. Among these, the Top 50 target genes were found to be significantly enriched in autophagy-related biological processes. Consistently, elevated levels of the autophagic markers Beclin 1 and LC3<i>β</i> were detected in calcified aortic valve tissues. Inhibition of lnc-COL6A1-6 significantly reduced autophagic flux in VICs under calcification-inducing conditions. Importantly, pharmacological inhibition of autophagy using chloroquine abolished the anticalcific effects of lnc-COL6A1-6 knockdown.</p><p><b>Conclusions:</b> The present study identified a lnc-COL6A1-6-mediated miRNA–mRNA regulatory network in aortic valve calcification. Knockdown of lnc-COL6A1-6 could mitigate VIC calcification by attenuating autophagic activity, highlighting its potential as a therapeutic target for CAVD.</p>","PeriodicalId":9582,"journal":{"name":"Cardiovascular Therapeutics","volume":"2025 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/cdr/2277191","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144935210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Relationship Between C-Reactive Protein–Triacylglycerol–Glucose Index and All-Cause Mortality in Patients With Cardiovascular Disease: A Retrospective Cohort Study and Development of a Machine Learning Prediction Model","authors":"Wenlong Ding,&nbsp;Fachao Shi,&nbsp;Zheng Wang,&nbsp;Long Wang,&nbsp;Caoyang Fang","doi":"10.1155/cdr/6914985","DOIUrl":"https://doi.org/10.1155/cdr/6914985","url":null,"abstract":"<p><b>Objective:</b> The CTI is increasingly recognized as a new marker for assessing inflammation and insulin resistance. However, the relationship between CTI and all-cause mortality risk in patients with CVD remains unclear.</p><p><b>Methods:</b> We analyzed data from the NHANES from 1999 to 2010. The correlation between CTI and all-cause mortality risk in CVD patients was examined using Cox regression analysis. Nonlinear relationships between CTI and all-cause mortality risk were explored through restricted cubic splines and Cox proportional hazards regression. We employed six ML models, including RF, LightGBM, DT, XGBoost, LR, and KNN, to predict all-cause mortality risk in CVD patients based on CTI and SHAP for interpretability.</p><p><b>Results:</b> A total of 1429 CVD patients were included, with 849 all-cause deaths recorded during the follow-up period. After adjusting for potential confounding factors, the highest quartile of CTI (Q4) significantly increased the risk of all-cause mortality compared to the lowest quartile (Q1) (HR = 1.38, 95% CI: 1.04–1.84, <i>p</i> = 0.03). Restricted cubic splines demonstrated a nonlinear relationship between CTI and all-cause mortality risk in CVD patients. Among the machine learning models, the LightGBM model exhibited the best predictive performance, with an ROC of 0.967, accuracy of 0.909, sensitivity of 0.906, specificity of 0.914, <i>F</i>1 score of 0.922, recall of 0.906, and PR of 0.979. SHAP analysis identified age, BU, and CTI as the primary predictive factors, with CTI positively correlated with all-cause mortality risk in CVD patients.</p><p><b>Conclusion:</b> There is a nonlinear relationship between CTI and all-cause mortality risk in CVD patients, with elevated CTI levels significantly associated with increased mortality risk. Additionally, for the first time, this study constructed a machine learning model to predict all-cause mortality risk in cardiovascular disease using CTI, with LightGBM demonstrating the best predictive performance. SHAP analysis identified age, BUN, and CTI as critical factors in the prediction, providing valuable references for future related research.</p>","PeriodicalId":9582,"journal":{"name":"Cardiovascular Therapeutics","volume":"2025 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/cdr/6914985","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144935209","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recent Advances in Renal Denervation Therapy and Novel Applications of High-Intensity Focused Ultrasound","authors":"JunHao Wang,&nbsp;Yu Ma,&nbsp;Ximing Li","doi":"10.1155/cdr/6692871","DOIUrl":"https://doi.org/10.1155/cdr/6692871","url":null,"abstract":"<p>Hypertension constitutes a major risk factor for cardiovascular diseases. Globally, the management and control of hypertension remain suboptimal. At present, pharmacological intervention is a critical strategy for patients with hypertension to achieve blood pressure regulation. Nevertheless, inadequate adherence to prescribed medication significantly impedes effective blood pressure control. Renal denervation (RDN) has emerged as a minimally invasive intervention that has the potential to achieve long-term reduction in blood pressure. Many preclinical and clinical trials have validated the effects of RDN. While trials such as SYMPLICITY HTN-3 raised questions about the efficacy of RDN, the majority of subsequent clinical trials have demonstrated benefits in patients with resistant hypertension. Presently, traditional RDN therapy is characterized by invasiveness and technical complexity, so the utilization of noninvasive high-intensity focused ultrasound (HIFU) has been incorporated into RDN procedures. This review is aimed at consolidating data on the efficacy and safety of various RDN modalities, examining the implementation of noninvasive HIFU in RDN practices, and suggesting potential avenues for future advancements and opportunities.</p>","PeriodicalId":9582,"journal":{"name":"Cardiovascular Therapeutics","volume":"2025 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/cdr/6692871","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144918637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}